by Richard Daverman, PhD
June 7, 2012 -- Hutchison MediPharma, the innovative China drug company that is majority owned by Chi-Med, released positive Phase I data for its two most advanced cancer-targeting molecules: Sulfatinib (HMPL-012) and Fruquintinib (HMPL-013). Both drug candidates were well-tolerated and showed preliminary evidence of efficacy against multiple tumor types. More details....
Stock Symbol: (AIM: CHM)
